Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Expands By 122.8%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totaling 579,800 shares, an increase of 122.8% from the September 15th total of 260,200 shares. Approximately 12.6% of the company’s stock are short sold. Based on an average trading volume of 305,800 shares, the short-interest ratio is currently 1.9 days. Based on an average trading volume of 305,800 shares, the short-interest ratio is currently 1.9 days. Approximately 12.6% of the company’s stock are short sold.

Vivos Therapeutics Price Performance

NASDAQ VVOS opened at $2.76 on Wednesday. Vivos Therapeutics has a 1-year low of $1.98 and a 1-year high of $7.95. The business’s fifty day moving average price is $3.69 and its 200-day moving average price is $3.49. The stock has a market capitalization of $20.70 million, a price-to-earnings ratio of -1.64 and a beta of 6.90. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.05 and a quick ratio of 1.05.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings results on Tuesday, August 19th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The business had revenue of $3.82 million during the quarter, compared to analysts’ expectations of $3.37 million. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%. On average, equities analysts predict that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on VVOS. Wall Street Zen lowered Vivos Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, Ascendiant Capital Markets lifted their price target on Vivos Therapeutics from $6.20 to $6.50 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $4.92.

Institutional Trading of Vivos Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VVOS. EWA LLC bought a new position in Vivos Therapeutics in the first quarter worth approximately $30,000. Cutter & CO Brokerage Inc. boosted its holdings in Vivos Therapeutics by 28.9% in the first quarter. Cutter & CO Brokerage Inc. now owns 49,100 shares of the company’s stock valued at $140,000 after purchasing an additional 11,000 shares during the last quarter. XTX Topco Ltd purchased a new stake in Vivos Therapeutics in the second quarter valued at $65,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics in the second quarter valued at $220,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.